Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Want to see VVOS full AI Analyst Report?
VVOS Stock Chart & Stats
$2.22
-$0.06(-1.47%)
At close: 4:00 PM EST
$2.22
-$0.06(-1.47%)
Day’s Range― - ―
52-Week Range$0.45 - $7.95
Previous CloseN/A
Volume144.69K
Average Volume (3M)421.86K
Market Cap
$6.95M
Enterprise Value$13.17M
Total Cash (Recent Filing)$2.11M
Total Debt (Recent Filing)$12.27M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 19, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding13,894,600
10 Day Avg. Volume324,525
30 Day Avg. Volume421,860
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-14.00
Price to Sales (P/S)1.20
P/FCF Ratio-1.18
Enterprise Value/Market Cap1.90
Enterprise Value/Revenue0.67
Enterprise Value/Gross Profit1.13
Enterprise Value/Ebitda-0.56
Forecast
1Y Price Target
$2.42Price Target Upside8.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.24
Revenue Forecast (FY)$23.25M
Bulls Say, Bears Say
Bulls Say
Revenue & Gross Margin ImprovementSustained top-line growth with a 10pp gross margin expansion shows the core treatment and services mix can deliver strong unit economics. Durable higher product-level margins create room to absorb SG&A while scaling, improving long-term profitability prospects if growth continues.
Patient Volume & Provider ProductivityRapidly rising patient volumes and measurable per-provider revenue gains indicate a scalable delivery model. Provider retraining that boosts daily throughput suggests recurring upside as new and existing clinicians ramp, supporting sustainable revenue per site and operating leverage over months.
Strategic Partnerships & Service ExpansionBuilding physician-aligned ventures and integrating diagnostics (e.g., SCN) diversifies referral channels and adds higher-margin services. Strategic collaborations that embed Vivos in medical workflows can produce recurring referral streams and higher contribution margins, strengthening long-term market position.
Bears Say
Negative Equity & Elevated DebtA negative equity position and meaningful debt load materially constrain financial flexibility and increase default or covenant risk. Structural capital weakness elevates refinancing and dilution risk and can limit ability to invest in growth or withstand adverse operational shocks over the medium term.
Persistent Cash Burn & Low LiquidityOngoing negative operating cash flow and a low cash runway make the business dependent on external financings. Reliance on repeated capital raises or debt restructurings is a durable risk that can dilute shareholders, distract management, and jeopardize execution of strategic initiatives if new funding is delayed or costly.
Large Operating Losses & Rising G&AMaterial operating losses and rapidly increasing G&A impair operating leverage and make path to sustained profitability uncertain. Unless structural cost reductions or outsized revenue scale materialize, elevated overhead will persistently suppress net margins and increase the need for dilutive capital solutions.
Vivos Therapeutics News
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $0.45 and its highest was $7.95 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $6.95M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 58 days.
How were Vivos Therapeutics’s earnings last quarter?
Currently, no data Available
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Undervalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 13,894,600 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivos Therapeutics
Vivos Therapeutics, Inc. is a medical technology enterprise dedicated to developing and commercializing advanced treatment solutions for adults facing conditions like dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring. The company's flagship product, the Vivos System, offers a unique multi-disciplinary therapy that stands out for being non-invasive, non-surgical, and free of pharmaceuticals, specifically addressing these dentofacial and sleep-related issues. Additionally, Vivos Therapeutics provides the VivoScore Program, a service encompassing comprehensive screening and convenient home sleep tests for both adults and children. The Vivos System is distributed and sold to licensed medical professionals, primarily general dentists, across the United States and Canada. Founded in 2016, Vivos Therapeutics, Inc. maintains its headquarters in Highlands Ranch, Colorado.
VVOS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted very strong top-line momentum—70% year-over-year revenue growth, 34% sequential growth, a 10 percentage-point gross margin improvement and rapidly rising patient volumes and KPIs driven by the SCN acquisition and provider productivity gains. However, these operational gains were offset by substantial increases in G&A and cash burn, a low cash balance (~$2.1M), increased discounts reducing product revenue, and an explicit need for additional financing and debt restructuring. Management presented multiple high-margin initiatives (pediatrics, insomnia services, medical affiliations) that could materially improve profitability, but near-term execution and capital availability remain material risks.View all VVOS earnings summariesVVOS Stock 12 Month Forecast
Average Price Target
$2.42
▲(8.86% Upside)
Technical Analysis
Iridex
―
Co-Diagnostics
―
Adagio Medical Holdings
―
Envoy Medical
―
Nexalin Technology, Inc.
―
Ownership Overview
9.74% Insiders
2.26% Mutual Funds
8.96% Other Institutional Investors
77.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---